The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
Open accessAbstract
Importance: The effectiveness of antipsychotic polypharmacy in schizophrenia relapse prevention is controversial, and use of multiple agents is generally believed to impair physical well-being. Objective: To study the association of specific antipsychotic combinations with psychiatric rehospitalization. Design, Setting, and Participants: In this nationwide cohort study, the risk of psychiatric rehospitalization was used as a marker for relapse among 62 250 patients with schizophrenia during the use of 29 different antipsychotic monotherapy and polypharmacy types between January 1, 1996, and December 31, 2015, in a comprehensive, nationwide cohort in Finland. We conducted analysis of the data from April 24 to June 15, 2018. Rehospitalization risks were investigated by using within-individual analyses to minimize selection bias. Main Outcomes and Measures: Hazard ratio (HR) for psychiatric rehospitalization during use of polypharmacy vs during monotherapy within the same individual. Results: In the total cohort, including 62 250 patients, 31 257 individuals (50.2%) were men, and the median age was 45.6 (interquartile range, 34.6-57.9) years. The clozapine plus aripiprazole combination was associated with the lowest risk of psychiatric rehospitalization in the total cohort, being superior to clozapine, the monotherapy associated with the best outcomes, with a difference of 14% (HR, 0.86; 95% CI, 0.79-0.94) in the analysis including all polypharmacy periods, and 18% in the conservatively defined polypharmacy analysis excluding periods shorter than 90 days (HR, 0.82; 95% CI, 0.75-0.89; P < .001). Among patients with their first episode of schizophrenia, these differences between clozapine plus aripiprazole vs clozapine monotherapy were greater (difference, 22%; HR, 0.78; 95% CI, 0.63-0.96 in the analysis including all polypharmacy periods, and difference, 23%; HR, 0.77; 95% CI, 0.63-0.95 in the conservatively defined polypharmacy analysis). At the aggregate level, any antipsychotic polypharmacy was associated with a 7% to 13% lower risk of psychiatric rehospitalization compared with any monotherapy (ranging from HR, 0.87; 95% CI, 0.85-0.88, to HR, 0.93; 95% CI, 0.91-0.95; P < .001). Clozapine was the only monotherapy among the 10 best treatments. Results on all-cause and somatic hospitalization, mortality, and other sensitivity analyses were in line with the primary outcomes. Conclusions and Relevance: Combining aripiprazole with clozapine was associated with the lowest risk of rehospitalization, indicating that certain types of polypharmacy may be feasible in the treatment of schizophrenia. Because add-on treatments are started when monotherapy is no longer sufficient to control for worsening of symptoms, it is likely that the effect sizes for polypharmacy are underestimates. Although the results do not indicate that all types of polypharmacy are beneficial, the current treatment guidelines should modify their categorical recommendations discouraging all antipsychotic polypharmacy in the maintenance treatment of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., Tanskanen, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1322 · Cited by 670
Self-citationTiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619
Self-citationMedication for Attention Deficit–Hyperactivity Disorder and Criminality
Lichtenstein, P., Halldner, L., Zetterqvist, J., Sjölander, A., Serlachius, E., Fazel, S., Långström, N., & Larsson, H. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203241 · Cited by 611
Kane, J. M., Kishimoto, T., & Correll, C. U. (2013) · World Psychiatry · doi:10.1002/wps.20060 · Cited by 520
Self-citationCorrell, C. U., Rummel-Kluge, C., Corves, C., Kane, J. M., & Leucht, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn018 · Cited by 397
Self-citationSchizophrenia, neuroleptic medication and mortality
Joukamaa, M., Heliövaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.2.122 · Cited by 395
Gallego, J. A., Bonetti, J., Zhang, J., Kane, J. M., & Correll, C. U. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.03.018 · Cited by 332
Self-citationWaddington, J. L., Youssef, H. A., & Kinsella, A. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.173.4.325 · Cited by 267
Polypharmacy With Antipsychotics, Antidepressants, or Benzodiazepines and Mortality in Schizophrenia
Tiihonen, J. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1532 · Cited by 253
Self-citationDoes antipsychotic polypharmacy increase the risk for metabolic syndrome?
Correll, C. U., Frederickson, A. M., Kane, J. M., & Manu, P. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.08.017 · Cited by 252
Self-citationGalling, B., Roldán, A., Hagi, K., Rietschel, L., Walyzada, F., Zheng, W., Cao, X., Xiang, Y., Zink, M., Kane, J. M., et al. (2017) · World Psychiatry · doi:10.1002/wps.20387 · Cited by 239
Self-citationFrom prescription drug purchases to drug use periods – a second generation method (PRE2DUP)
Tanskanen, A., Taipale, H., Koponen, M., Tolppanen, A.-M., Hartikainen, S., Ahonen, R., & Tiihonen, J. (2015) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-015-0140-z · Cited by 199
Self-citationTiihonen, J., Tanskanen, A., & Taipale, H. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17091001 · Cited by 196
Self-citationKishimoto, T., Agarwal, V, Kishi, T., Leucht, S., Kane, J. M., & Correll, C. U. (2013) · Molecular Psychiatry · doi:10.1038/mp.2011.143 · Cited by 169
Self-citationSommer, I. E., Begemann, M. J. H., Temmerman, A., & Leucht, S. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr004 · Cited by 159
Taipale, H., Mehtälä, J., Tanskanen, A., & Tiihonen, J. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx176 · Cited by 153
Self-citationDoes the Addition of a Second Antipsychotic Drug Improve Clozapine Treatment?
Barbui, C., Signoretti, A., Mule, S., Boso, M., & Cipriani, A. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn030 · Cited by 153
Baandrup, L., Gasse, C., Jensen, V. D., Glenthoj, B. Y., Nordentoft, M., Lublin, H., Fink‐Jensen, A., Lindhardt, A., & Mortensen, P. B. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04818yel · Cited by 137
Augmentation of clozapine with a second antipsychotic – a meta‐analysis
Taylor, D. M., Smith, L. A., Gee, S., & Nielsen, J. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01792.x · Cited by 131
Correll, C. U., & Gallego, J. A. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2012.06.007 · Cited by 125
Self-citationAntipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behavior
Correll, C. U., Shaikh, L., Gallego, J. A., Nachbar, J., Olshanskiy, V., Kishimoto, T., & Kane, J. M. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.02.016 · Cited by 97
Self-citationKatona, L., Czobor, P., & Bitter, I. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.10.034 · Cited by 76
Galling, B., Roldán, A., Rietschel, L., Hagi, K., Walyzada, F., Zheng, W., Cao, X., Xiang, Y., Kane, J. M., & Correll, C. U. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1165668 · Cited by 48
Self-citationMid-Term and Long-Term Efficacy and Effectiveness of Antipsychotic Medications for Schizophrenia
Glick, I. D., Correll, C. U., Altamura, A. C., Marder, S. R., Csernansky, J. G., Weiden, P. J., Leucht, S., & Davis, J. M. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11r06927 · Cited by 47
Self-citationAntipsychotic polypharmacy: A Japanese survey of prescribers' attitudes and rationales
Kishimoto, T., Watanabe, K., Uchida, H., Mimura, M., Kane, J. M., & Correll, C. U. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.03.014 · Cited by 37
Self-citationUrsoniu, S., Mikhailidis, D. P., Șerban, M.-C., Penson, P. E., Toth, P. P., Ridker, P. M., Ray, K. K., Hovingh, G. K., Kastelein, J. J. P., Hernández, A. V., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.06.002 · Cited by 32
Kane (2013) · doi:10.1002/wps.v12.3 · Cited by 16
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Kaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
Baandrup, L. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13384 · Cited by 79
Matsui, K., Tokumasu, T., Takekita, Y., Inada, K., Kanazawa, T., Kishimoto, T., Takasu, S., Tani, H., Tarutani, S., Hashimoto, N., et al. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.05.030 · Cited by 41
Polypharmacy- Purpose, Benefits and Limitations
Grover, D., Tom, M., Maguire, G., & Stahl, S. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220107153813 · Cited by 7
Metadata
- Authors
- Tiihonen, J., Taipale, H., Mehtälä, J., Vattulainen, P., Correll, C. U., & Tanskanen, A.
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2019-05-01
- Volume
- 76
- Issue
- 5
- Pages
- 499
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W2916393779
- Cited by
- 297
- References
- 27
- FWCI
- 28.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.